DDInter1476 DDInter927
Pirbuterol is a beta-2 adrenergic bronchodilator. In vitro studies and in vivo pharmacologic studies have demonstrated that pirbuterol has a preferential effect on beta-2 Adrenergic receptors compared with isoproterenol. While it is recognized that beta-2 adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta-2 receptors in the human heart, existing in a concentration between 10-50%. The precise function of these receptors has not been established. The pharmacologic effects of beta adrenergic agonist drugs, including pirbuterol, are at least in proof attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (AlP) to cyclic-3†,5†-adenosine monophosphate (c-
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Pirbuterol {u} (Compound) resembles {v} (Compound) Bupranolol
Pirbuterol {u} (Compound) resembles {v} (Compound) Terbutaline
Pirbuterol {u} (Compound) treats {v} (Disease) asthma
Pirbuterol {u} (Compound) binds {v} (Gene) ADRB1
Pirbuterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Pirbuterol {u} (Compound) causes {v} (Side Effect) Dry mouth
Pirbuterol (Compound) resembles Bupranolol (Compound)
Pirbuterol (Compound) resembles Terbutaline (Compound)
Pirbuterol (Compound) treats asthma (Disease)
Pirbuterol (Compound) binds ADRB1 (Gene)
Pirbuterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class)
Pirbuterol (Compound) causes Dry mouth (Side Effect)